Crescendo Biologics Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Private

  • Employees
  • 38

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 18

Crescendo Biologics General Information

Description

Operator of a clinical-stage immuno-oncology company intended to develop potent, multi-functional human body therapeutics in oncology. The company specializes in multi-functional drugs based on its patent-protected, transgenic mouse platform generating fully human viewport height domain building blocks, enabling researchers to build medicines capable of delivering safe durable responses to patients.

Contact Information

Formerly Known As
Translocus
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Meditrina Building 260
  • Babraham Research Campus
  • Cambridge CB22 3AT
  • England, United Kingdom
+44 01223
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Corporate Office
  • Meditrina Building 260
  • Babraham Research Campus
  • Cambridge CB22 3AT
  • England, United Kingdom
+44 01223

Crescendo Biologics Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Crescendo Biologics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Secondary Transaction - Private Completed Clinical Trials - Phase 1
11. Later Stage VC 24-Jul-2023 Completed Clinical Trials - Phase 1
10. Debt - General 01-Jan-2023 Completed Clinical Trials - Phase 1
9. Later Stage VC 10-Jan-2022 Completed Clinical Trials - Phase 1
8. Later Stage VC 15-Feb-2021 Completed Clinical Trials - Phase 1
7. Later Stage VC (Series B) 30-Apr-2018 Completed Clinical Trials - Phase 1
6. Later Stage VC 10-Oct-2016 Completed Clinical Trials - Phase 1
5. Grant 27-May-2015 Completed Clinical Trials - Phase 1
4. Later Stage VC (Series A) 03-Apr-2014 $33.7M $46.1M Completed Clinical Trials - Phase 1
3. Later Stage VC 05-Oct-2012 $5.17M $12.4M Completed Clinical Trials - Phase 1
To view Crescendo Biologics’s complete valuation and funding history, request access »

Crescendo Biologics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B Preferred
Series B Preferred
Series B Preferred
Series A
Series A Preferred 648,426 $0.000013 $1.18 $1.18 1x $1.18 0.39%
Series A 4,695,000 $0.000013 $1.34 $1.34 1x $1.34 2.81%
To view Crescendo Biologics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Crescendo Biologics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage immuno-oncology company intended to develop potent, multi-functional human body therapeutic
Drug Discovery
Cambridge, United Kingdom
38 As of 2024

Abingdon, United Kingdom
 

Schlieren, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Crescendo Biologics Competitors (66)

One of Crescendo Biologics’s 66 competitors is Adaptimmune Therapeutics, a Formerly VC-backed company based in Abingdon, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Memo Therapeutics Venture Capital-Backed Schlieren, Switzerland
Pathios Therapeutics Venture Capital-Backed Abingdon, United Kingdom
Nektar Therapeutics Formerly VC-backed San Francisco, CA
Ncardia Venture Capital-Backed Leiden, Netherlands
You’re viewing 5 of 66 competitors. Get the full list »

Crescendo Biologics Patents

Crescendo Biologics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202319982-D0 Therapeutic molecules Pending 22-Dec-2023
GB-202317996-D0 Combination therapy Pending 24-Nov-2023
GB-202317997-D0 Therapeutic molecules Pending 24-Nov-2023
GB-202315938-D0 Therapeutic molecules Pending 18-Oct-2023
GB-202205589-D0 Mesothelin binders Inactive 14-Apr-2022 C07K16/28
To view Crescendo Biologics’s complete patent history, request access »

Crescendo Biologics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Crescendo Biologics Investors (18)

Investor Name Investor Type Holding Investor Since Participating Rounds
Kreos Capital Lender/Debt Provider Minority
BioNTech Corporation Minority
Andera Partners PE/Buyout Minority
IP Group Venture Capital Minority
Quan Capital Venture Capital Minority
You’re viewing 5 of 18 investors. Get the full list »

Crescendo Biologics FAQs

  • When was Crescendo Biologics founded?

    Crescendo Biologics was founded in 2007.

  • Where is Crescendo Biologics headquartered?

    Crescendo Biologics is headquartered in Cambridge, United Kingdom.

  • What is the size of Crescendo Biologics?

    Crescendo Biologics has 38 total employees.

  • What industry is Crescendo Biologics in?

    Crescendo Biologics’s primary industry is Drug Discovery.

  • Is Crescendo Biologics a private or public company?

    Crescendo Biologics is a Private company.

  • What is Crescendo Biologics’s current revenue?

    The current revenue for Crescendo Biologics is .

  • How much funding has Crescendo Biologics raised over time?

    Crescendo Biologics has raised $274M.

  • Who are Crescendo Biologics’s investors?

    Kreos Capital, BioNTech, Andera Partners, IP Group, and Quan Capital are 5 of 18 investors who have invested in Crescendo Biologics.

  • Who are Crescendo Biologics’s competitors?

    Adaptimmune Therapeutics, Memo Therapeutics, Pathios Therapeutics, Nektar Therapeutics, and Ncardia are some of the 66 competitors of Crescendo Biologics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »